UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

_____________

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 10, 2008

 

Antares Pharma, Inc.

 

 

Registrant’s telephone number, including area code: 609-359-3020

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

 

 

 

 

 

On October 10, 2008, Jack E. Stover, the Chief Executive Officer of Antares Pharma, Inc., a Delaware corporation (the “Company”), and a member of the Company’s Board of Directors (the “Board”), resigned from his position as Chief Executive Officer and as a member of the Board.

 

A copy of the Company’s press release announcing Mr. Stover’s resignation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

 

Also on October 10, 2008, the Board appointed Paul K. Wotton, Ph.D., as the Company’s Chief Executive Officer. Dr. Wotton, age 48, has served as the Company’s President and Chief Operating Officer since July 7, 2008 and as a member of the Board since August 17, 2004. As a result of Dr. Wotton’s appointment as Chief Executive Officer, he will no longer serve as the Company’s Chief Operating Officer but will retain the title of President. In addition, Dr. Wotton will serve as the Company’s principal executive officer. Prior to joining the Company, Dr. Wotton served as President and Chief Executive Officer of Topigen Pharmaceuticals, Inc., a biotechnology company based in Montreal, Canada, from May 2004 until March 2008. Prior to joining Topigen, Dr. Wotton was the Head of Global Business Development at SkyePharma, a United Kingdom company listed on the London Stock Exchange and quoted on Nasdaq, from January 2002 until May 2004. Dr. Wotton also previously served as Vice President of Corporate Development for Eurand and Vice President of Business Development for Penwest Pharmaceuticals Co. Dr. Wotton is a member of Genaera Corporation’s Board of Directors.

 

On July 7, 2008, Dr. Wotton and the Company entered into an Employment Agreement whereby the Company appointed Dr. Wotton as its President and Chief Operating Officer (the “Employment Agreement”). The Employment Agreement is described in more detail in the Company’s Current Report on Form 8-K filed on July 7, 2008. Any changes to the Employment Agreement relating to Dr. Wotton’s appointment as Chief Executive Officer will be disclosed as required under the Securities Exchange Act of 1934, as amended, and applicable regulations of the United States Securities and Exchange Commission once such changes become available.

 

Other Changes to the Board

 

Also on October 10, 2008, the Board appointed Leonard S. Jacob, M.D., Ph.D., as the Chairman of the Board. Dr. Jacob, 59, has served as a member of the Board since January 16, 2007. Jacques Gonella, Ph.D., the Company’s former Chairman, will continue to serve as a member of the Board. A copy of the Company’s press release announcing Dr. Jacob’s appointment as Chairman of the Board is attached as Exhibit 99.2 to this Current Report on Form 8-K.

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

EXHIBIT INDEX